Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,200,354 shares, an increase of 67.2% from the July 15th total of 718,008 shares. Currently, 8.0% of the company’s shares are sold short. Based on an average daily volume of 316,846 shares, the days-to-cover ratio is presently 3.8 days.

Cel-Sci Trading Up 0.6%

Shares of CVM traded up $0.01 during midday trading on Monday, hitting $1.55. The stock had a trading volume of 129,421 shares, compared to its average volume of 269,824. The stock’s 50 day moving average is $1.23 and its 200 day moving average is $2.68. The firm has a market cap of $27.09 million, a PE ratio of -0.16 and a beta of 0.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. Cel-Sci has a 1 year low of $0.89 and a 1 year high of $13.48.

Cel-Sci (NYSEAMERICAN:CVM) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.47) EPS for the quarter.

Institutional Investors Weigh In On Cel-Sci

A number of institutional investors and hedge funds have recently modified their holdings of CVM. HighTower Advisors LLC bought a new position in Cel-Sci in the 4th quarter valued at $53,000. HRT Financial LP bought a new stake in shares of Cel-Sci during the fourth quarter worth $60,000. XTX Topco Ltd purchased a new stake in shares of Cel-Sci during the fourth quarter valued at $66,000. US Bancorp DE purchased a new stake in shares of Cel-Sci during the third quarter valued at $80,000. Finally, Renaissance Technologies LLC bought a new position in shares of Cel-Sci in the fourth quarter worth about $81,000. 12.08% of the stock is owned by institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.